Gainers
- MEDIROM Healthcare Techs MRM shares elevated by 79.8% to $1.1 throughout Thursday’s after-market session. The corporate’s market cap stands at $8.6 million.
- Purple Innovation PRPL shares moved upwards by 30.36% to $0.86. The corporate’s market cap stands at $93.0 million. The corporate’s, This autumn earnings got here out immediately.
- Cheetah Web Provide Chain CTNT shares rose 6.46% to $1.74. The market worth of their excellent shares is at $5.5 million.
- Ulta Magnificence ULTA shares moved upwards by 6.05% to $333.5. The market worth of their excellent shares is at $15.4 billion. As per the information, the This autumn earnings report got here out immediately.
- Afya AFYA inventory rose 5.98% to $17.19. The market worth of their excellent shares is at $1.5 billion.
- Motorcar Components of America MPAA inventory rose 5.81% to $10.74. The market worth of their excellent shares is at $210.3 million.
Losers
- Xponential Health XPOF shares fell 21.6% to $9.5 throughout Thursday’s after-market session. The corporate’s market cap stands at $306.7 million. As per the information, the This autumn earnings report got here out immediately.
- MKDWell Tech MKDW inventory decreased by 18.54% to $0.32. The market worth of their excellent shares is at $5.9 million.
- Linkage World LGCB shares decreased by 16.49% to $0.19. The market worth of their excellent shares is at $5.9 million.
- Damon DMN shares decreased by 9.48% to $0.15. The corporate’s market cap stands at $3.2 million.
- Jeffs Manufacturers JFBR inventory fell 7.3% to $1.27. The corporate’s market cap stands at $2.2 million.
- Zumiez ZUMZ shares decreased by 6.11% to $12.0. The corporate’s market cap stands at $230.0 million. As per the information, the This autumn earnings report got here out immediately.
See Additionally: www.benzinga.com/cash/best-consumer-cyclical-stocks/
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
Momentum30.28
Progress48.04
High quality41.56
Worth41.07
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.